Daina Graybosch
Stock Analyst at Leerink Partners
(0.83)
# 3,808
Out of 4,931 analysts
110
Total ratings
35.9%
Success rate
-11.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daina Graybosch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XLO Xilio Therapeutics | Initiates: Outperform | $2 | $0.65 | +205.58% | 1 | Aug 6, 2025 | |
| ADAG Adagene | Initiates: Outperform | $7 | $2.33 | +200.97% | 1 | Aug 6, 2025 | |
| SMMT Summit Therapeutics | Initiates: Underperform | $12 | $27.87 | -56.94% | 1 | Jun 11, 2025 | |
| ITOS iTeos Therapeutics | Downgrades: Market Perform | $47 → $9 | $10.13 | -11.11% | 8 | May 14, 2025 | |
| MRK Merck & Co. | Maintains: Outperform | $136 → $119 | $80.14 | +48.49% | 19 | Jan 13, 2025 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $11 → $2 | $1.54 | +29.87% | 6 | Dec 12, 2024 | |
| BOLT Bolt Biotherapeutics | Downgrades: Market Perform | $60 → $20 | $5.89 | +239.56% | 8 | May 15, 2024 | |
| ACLX Arcellx | Maintains: Outperform | $35 → $39 | $70.17 | -44.42% | 5 | Mar 30, 2023 | |
| NKTR Nektar Therapeutics | Maintains: Market Perform | $75 → $45 | $21.90 | +105.48% | 10 | Feb 24, 2023 | |
| IPSC Century Therapeutics | Maintains: Outperform | $20 → $14 | $0.53 | +2,554.03% | 4 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $62 → $10 | $0.99 | +906.44% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $9 | $2.14 | +320.56% | 10 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $38 | $9.45 | +302.12% | 2 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $30 → $8 | $3.70 | +116.22% | 4 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $223 → $224 | $111.39 | +101.10% | 16 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $2.05 | +1,366.99% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $17 | $1.18 | +1,340.68% | 3 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $9 | $1.49 | +504.03% | 4 | Feb 25, 2022 |
Xilio Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $2
Current: $0.65
Upside: +205.58%
Adagene
Aug 6, 2025
Initiates: Outperform
Price Target: $7
Current: $2.33
Upside: +200.97%
Summit Therapeutics
Jun 11, 2025
Initiates: Underperform
Price Target: $12
Current: $27.87
Upside: -56.94%
iTeos Therapeutics
May 14, 2025
Downgrades: Market Perform
Price Target: $47 → $9
Current: $10.13
Upside: -11.11%
Merck & Co.
Jan 13, 2025
Maintains: Outperform
Price Target: $136 → $119
Current: $80.14
Upside: +48.49%
LAVA Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: $11 → $2
Current: $1.54
Upside: +29.87%
Bolt Biotherapeutics
May 15, 2024
Downgrades: Market Perform
Price Target: $60 → $20
Current: $5.89
Upside: +239.56%
Arcellx
Mar 30, 2023
Maintains: Outperform
Price Target: $35 → $39
Current: $70.17
Upside: -44.42%
Nektar Therapeutics
Feb 24, 2023
Maintains: Market Perform
Price Target: $75 → $45
Current: $21.90
Upside: +105.48%
Century Therapeutics
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $14
Current: $0.53
Upside: +2,554.03%
Jan 6, 2023
Maintains: Outperform
Price Target: $62 → $10
Current: $0.99
Upside: +906.44%
Nov 15, 2022
Maintains: Outperform
Price Target: $10 → $9
Current: $2.14
Upside: +320.56%
Nov 3, 2022
Maintains: Outperform
Price Target: $40 → $38
Current: $9.45
Upside: +302.12%
Aug 29, 2022
Downgrades: Market Perform
Price Target: $30 → $8
Current: $3.70
Upside: +116.22%
Jul 29, 2022
Maintains: Outperform
Price Target: $223 → $224
Current: $111.39
Upside: +101.10%
Jul 18, 2022
Initiates: Outperform
Price Target: $30
Current: $2.05
Upside: +1,366.99%
May 11, 2022
Maintains: Outperform
Price Target: $18 → $17
Current: $1.18
Upside: +1,340.68%
Feb 25, 2022
Maintains: Outperform
Price Target: $16 → $9
Current: $1.49
Upside: +504.03%